Protein Expression Market Worth $3.0 Billion By 2025

The global protein expression market is expected to reach USD 3.0 billion by the year 2025 growing at a CAGR of 10.4%, according to a new report by Grand View Research, Inc. The growing demand for biologics and expansion of the biopharmaceutical industry have resulted in massive growth of the protein expression market. Rising demand for therapeutic proteins such as insulin, hormones, monoclonal antibodies, and vaccines is a major factor that propels growth of the market during forecast period. Thus, many biotechnology and pharmaceuticals companies have begun to concentrate on the development and manufacturing of advanced therapeutic proteins for the treatment of severe chronic diseases such as cancer, hemophilia, infectious diseases, anemia, and multiple sclerosis.

Increasing investment in the R&D, by biotechnology and pharmaceutical companies, is another major factor supporting the sector growth. The availability of new and advanced technologies to cater the needs of drugs & biologics product manufacturers boosts the adoption of protein expression products for research and manufacturing applications. In addition, several pharmaceutical and biotechnology manufacturers are undergoing collaborations and partnerships to achieve leadership in the sector. For instance, in December 2016, Takara Bio, Inc. signed a merger agreement with Rubicon Genomics, Inc. to strengthen its genomics business.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/protein-expression-market

Further Key Findings From The Report Suggest:

Prokaryotic expression systems segment was the largest revenue-generating amongst others owing to its large application in biologics and drug productions
Mammalian cell expression systems is the fastest growing segment of the protein expression market owing to its growing demand for proteomics research and biologics manufacturing
Reagents segment held the largest revenue share in the market, which is attributed to its repetitive purchase for therapeutic, industrial, and research applications
The services segment is projected to grow at highest rate due to increasing trend of outsourcing of protein expression services by research labs and drug manufacturers
Therapeutic application segment was leading in 2016, due to high demand of therapeutic proteins for the treatment of cancer, infectious diseases, anemia, hemophilia, and multiple sclerosis
The pharmaceutical and biotechnological companies segment dominated the sector in terms of revenue in 2016 due to rising focus on proteomics research and increasing production of biologics products
North America was the leading regional market in 2016 and is expected to maintain its dominance during the forecast period, because of the presence of large number of biopharmaceutical and biotechnology companies in this region
The Asia Pacific region is projected to grow at a highest CAGR during the forecast period owing to untapped opportunities in the developing countries including China and India
Some of the major players include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, New England Biolabs, Promega Corporation, Qiagen, and Takara Bio, Inc.

Pancreatic Cancer Treatment Market Size Worth $4.2 Billion By 2025

The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period.

According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/pancreatic-cancer-treatment-market

Further key findings from the study suggest:

The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting for more than 95% of the overall pancreatic cancer types
Among the treatment types, targeted therapy occupied the largest share since it is considered as the most effective treatment option, which blocks the growth and spread of cancer cells without damaging healthy cells
North America dominated the segment with the largest revenue share in 2015 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure
Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment
Some of the major companies operating in this market are, but are not limited to, Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.

Acute Repetitive Seizures Market Size Worth $3.19 Billion By 2025

The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc. The report also states that the market will expand at a strong CAGR of 47.8% during the forecast period. Rise in the number of initiatives to increase awareness about epilepsy is the major factor driving the market.

The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with a few major companies and a high market share.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.

There are several routes of drug administration; out of which, the nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/acute-repetitive-seizures-market

Further key findings from the study suggest:

Global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period
Diastat rectal gel was the dominant product segment in 2017 due to the efficacy of the route of administration and affordability of the product
USL-261 is expected to witness a lucrative CAGR over the forecast period. USL-21 has an edge over the other drugs owing to its superior clinical profile and positive phase III results
North America held the largest share in 2017 due to factors, such as growing initiatives for raising awareness about epilepsy and seizures
Germany is anticipated to witness lucrative growth over the next decade owing to technological advancements in scientific, clinical, and medical fields
Some of the key companies in the market are UCB S.A.; Neurelis, Inc.; and Alexza Pharmaceuticals, Inc. These companies are likely to dominate the market and gain maximum share over the forecast period

Neuroendocrine Tumor Treatment Market Size Worth $3.33 Billion By 2025

The global neuroendocrine tumor (NET) treatment market size is expected to reach USD 3.33 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to register a CGAR of 10.4% during the forecast period. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.

For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/neuroendocrine-tumor-net-treatment-market

Further key findings from the study suggest:

Somatostatin analogs segment accounted for the largest revenue share of more than 60% in 2017 owing to its cost-effective and safe therapy procedure
The pancreas segment is expected to exhibit the highest growth in the neuroendocrine tumor treatment market over the forecast period
Clinics segment is expected to register the highest CAGR of 10.9% over the estimated period due to increasing patient preference for clinics over other healthcare settings
North America held the largest share of the global neuroendocrine tumor treatment market in 2017 mainly due to favorable government insurance policies
Some of the key companies in the global market are Pfizer, Inc.; Novartis AG; Ipsen Pharma; and Boehringer Ingelheim International GmbH. Major companies focus more on R&D to develop novel therapeutics for NETs.

Nasal Drug Delivery Systems Market Worth $67.99 Billion By 2025

The global nasal drug delivery systems market size is expected to reach USD 67.99 billion by 2025 expanding at 6.5% CAGR, according to a new report by Grand View Research, Inc. Rising awareness about nasal products is one of the major factors driving the market. Growing geriatric population is also expected to have positive impact on the market. According to the United Nations Department of Economic and Social Affairs, the global geriatric population (60 years and above), was around 962 million in 2017. The number is expected to grow, particularly in Latin America with 71% rise in population aged 60 and over, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%).

Moreover, ongoing product development and their expected commercialization will propel market growth over the forecast period. For instance, In April 2018, Dr. Reddy’s Laboratories, along with its subsidiary Promius Pharma, LLC, announced filing of their New Drug Application (NDA) for DFN-02, for the treatment of migraine. Increasing adoption of self-administration practices and focus on other alternative routes of drug delivery, such as nasal drug delivery, also offer growth opportunities for the market. Some of the key companies in the industry are AstraZeneca PLC; OptiNose, Inc.; Pfizer, Inc.; Becton, Dickinson and Company; Promius Pharma LLC; B.F. Ascher & Company, Inc.; and Cadila Pharmaceuticals Ltd.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/nasal-drug-delivery-technology-system-market

Further key findings from the report suggest:

Nasal sprays led the dosage type segment in 2017 due to increased prevalence of asthma and other infectious diseases
On the other hand, nasal drops segment witnessed the fastest growth in 2017 owing to availability of cost-effective products with better efficacy
Non-pressurized containers segment led the market in 2017 due to continous development in nasal powders and gel products
Asthma was the dominant therapeutic application segment in 2017 and is estimated to be the fastest-growing segment with a CAGR of 7.0% during the forecast years due to increasing disease prevalence
Geographically, North America held the largest share in 2017. Asia Pacific is estimated to witness the fastest CAGR of 7.5% due to presence of key companies, such as Cipla Inc.
Some of the leading companies in the global nasal drug delivery technology market are GlaxoSmithKline PLC; AstraZeneca PLC; Pfizer, Inc.; OptiNose, Inc.; Becton, Dickinson and Company; Promius Pharma, LLC; Cadila Pharmaceuticals Ltd.; B.F. Ascher & Company, Inc.; PendoPharm, Inc.; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty. Ltd.; and NAVEH Pharma Ltd.

Antibiotic Resistance Market Worth $12.07 Billion by 2025

The global antibiotic resistance market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.

Biotech companies that are developing therapies for antibiotic-resistant infections include Melinta Therapeutics, Achaogen, and Nabriva Therapeutics. On the other hand, majority of large pharmaceutical companies don’t find this market lucrative enough due to slower growth in revenues for marketed drugs and lower return on investments. For instance, Novartis recently discontinued development of its antibacterial drugs for antibiotic resistance.

Manufacturers can obtain the Qualified Infectious Disease Product (QIDP) designation, which escalates the clinical review process for antibacterial therapies targeting high priority pathogens. The QIDP designation enables faster access to targeted agents and was introduced under the GAIN (Generating Antibiotic Incentives Now) Act, passed in 2012 as an extension to the U.S. FDA Safety and Innovation Act. The legislation aims to encourage the development of novel therapies for growing burden and severity of infections with antibiotic resistance.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/antibiotic-resistance-market

Further key findings from the report suggest:

In 2017, the market by cUTI disease registered significant sales due to elevated rate of resistance in extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae and P. aeruginosa strains
The combination therapies segment, which includes fixed-dose combinations of beta lactams and beta lactamase inhibitors, is projected to witness the fastest growth rate over the forecast period
Infections due to E. coli pathogens that are ESBL-producing and carbapenem-resistant led in terms of sales revenue in 2017 due to high treatment cost
On the geographical front, North America was the dominant revenue contributor in the market in 2017. Improving reimbursement scenario with new technology add-on payment provision is promoting the use of novel products in this region
Among pharmaceutical companies, Merck, Allergan, and Pfizer were the key players with top-selling drugs in the antibiotic resistance market in 2017.

Polyglycerol Market Size Worth $3.83 Billion By 2025

The global polyglycerol market size is expected to reach at USD 3.83 billion by 2025 expanding at a CAGR of 9.0% during the forecast period, according to a new report by Grand View Research, Inc. Polyglyceryl-3 diisostearate, polyglyceryl-3 dimer dilinoleate, and polyglyceryl-3 ricinoleate are some of the key polyglycerol 3 esters. Polyglycerol esters are plant/vegetable-derived, which makes them renewable and eco-friendly. Thus, favorable regulations pertaining to the use of polyglycerol and its esters is likely to be the major factor driving the market.Fluctuating prices of raw materials and availability of substitutes may hamper the market growth.

Moreover, the potential supply-demand gap for glycerol, which is expected in near future, followed by the presence of enzymes are expected cause hindrance to the market growth. However, rapidly growing personal care and F&B industries coupled with increasing pharmaceutical investments is expected to propel the product demand. Polyglycerol is used as cosmetic additives in personal care industry. The personal care industry is witnessing accelerated growth across the globe owing to factors like increasing disposable income, access to online platforms, and demand for anti-aging, natural, and gender-specific products. The F&B application segment accounted for 30.2% of the overall volume share in 2017.

Increasing demand for food additives in bakery products, chocolate production, and other food-related markets is expected to boost the market growth over the forecast period. Polyglycerol is also used in other applications, such as drilling fluids, textile lubricants, and wastewater treatment. Increasing oil and shale exploration activities in North America and Africa are expected to augment the market development. Also, emphasis on the improvement of water treatment facilities owing to strict government regulations is likely to propel the product demand in near future. Led by U.S., North America is a prominent regional market on account of high demand for bakery items, cosmetics, and liquid detergents in the region.

Moreover, recovering of pharmaceutical industry in U.S. is expected to boost the demand further, thereby augmenting regional market expansion. Pioneers in the global market have undertaken several strategies, such as new product development, extensive R&D activities, and expansion of customer base, to gain competitive advantage over others. For example, in July 2017, Lonza acquired Capsugel S.A. for USD 5.5 billion to boost its growth and ability to cater to customers of pharmaceutical, healthcare, and nutrition industries.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/polyglycerol-market

Further key findings from the report suggest:

PG-4 was the largest product segment in 2017 and it accounted for a share of 28.2% of the overall revenue, owing to its wide application scope
Food & beverage is forecasted to be the fastest-growing application segment over forecast period
In 2017, China accounted for 45.6% of the APAC polyglycerol market, in terms of volume, due to rapid growth of the end-use industries in the country
In terms of volume, PG-10 is expected to be the fastest-growing segment in APAC owing to the product’s extensive usage in personal care formulations
Some of the key participants include Cargill, Inc.; Sakamoto Yakuhin kogyo Co., Ltd.; Spiga Nord S.p.A.; and The Good Scents Company
Companies like Spiga Nord S.p.A and Procter & Gamble are integrated across the value chain, as both these companies are raw material suppliers as well as manufacturers

Oil Dispersible Color Market Worth $1.2 Billion By 2025

The global oil dispersible color market size is expected to reach USD 1.2 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.8% over the forecast period. Increasing number of confectionary and bakery products and Rise in the demand for food and beverages are likely to fuel the market growth in the upcoming years.

Shifting inclination towards environment friendly products and stringent government regulations on food safety are some of the factors that drive the global market. Technology advancements have been contributing significantly to the market growth. The natural product segment emerged as the largest segment in 2018 due to increase in awareness related to harmful effects of artificial colors.

For instance, in 2016, DDW, the largest producer of natural colors, have launched a new natural oil dispersible color derived from a non-GMO purple corn hybrid that is mostly cultivated in U.S. Technological advancements, coupled with growing demand for natural colors, are expected to drive the demand for natural oil dispersible color over the forecast period.

The food and beverages segment was the largest application segment in 2018. Increase in demand for bakery products and beverages is anticipated to drive the segment in the upcoming years. Rising demand for flavored frozen and dairy products has also fueled the segment growth. The pharmaceuticals segment is estimated to witness growth during the forecast period owing to increase in product demand in the pharmaceutical industry.

Europe was the largest regional market in 2018 owing to increasing demand for natural food color owing to stringent food safety regulations. Many countries of Europe have been the largest exporters of bakery and confectionary products. Belgium was found to be one of the largest producers of chocolates and candies in Europe. This, in turn, will boost demand for oil dispersible color in the region. Asia Pacific is estimated to be the fastest growing market for oil dispersible color due to increase in awareness related to negative effects of artificial coloring and growing demand from the cosmetic and pharmaceutical industries.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/oil-dispersible-color-market

Further key findings from the report suggest:

The natural product segment dominated the global oil dispersible color market with an overall revenue share of 81.8% in 2018. The synthetic segment is anticipated to ascend at a CAGR of 4.9% over the forecast period
The food and beverages application segment was valued at USD 478.5 million in 2018 and is projected to exhibit high growth in the next few years
Asia Pacific is anticipated to be the fastest growing market, expanding at a CAGR of 7.0% during the forecast period. China is the largest consumer due to growing demand from the food and beverages industry
Key industry players include DDW The Colour House; Archer Daniels Midland; Naturex; Chr. Hansen Holding A/S; Symrise; GNT International B.V.; Sensient Technologies Corporation; McCormick; Kalsec, Inc.; San-Ei Gen; and Colour Garden
Various manufacturers are concentrating on new product launches, capacity expansion, and technological innovation to estimate existing and future demand patterns from upcoming product segments.

Coffee Beans Market Size Worth $42.5 Billion By 2025

The global coffee beans market size is expected to reach USD 42.5 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 6.7% over the forecast period. Increasing consumption of coffee across various regions and health benefits related to the beverage are the major factors for the growth of market. Moreover, increase in the number of coffee retail shops and cafes in India and China, coupled with rise in consumption of this beverage among different age groups, especially young generation, has driven the demand for these beans.

Cup of coffee with roasted beans on table

Arabica dominated the market in 2018 and is expected to maintain its lead in the forecast period. Arabic is the mostly consumed owing to its sweet taste and high presence of lipids. Robusta beans is expected to be the fastest growing segment due to growing demand from the pharmaceutical industry owing to high caffeine content. Many manufacturers are focusing on improving their product to produce better quality of coffee.

For instance, in 2019, Lavazza launched a new cold coffee brew, which is made up of robusta bean. Furthermore, Roadchef, a motor service company, had tied up with bio-bean to use the recycle waste coffee beans into fuel, which is expected to have a positive effect on the market growth over the forecast period.

North America was the largest regional market in 2018 due to growing demand for coffee vending machines at railway stations and other places. Furthermore, increasing popularity of this beverage among the working population is anticipated to make a reasonable contribution to the market revenue. Furthermore, increase in the number of coffee shops in Canada and U.S. has led to a rise in consumption of robusta and arabica beans in recent years.

MEA is estimated to expand at the fastest CAGR of 9.9% over the forecast period owing to increasing consumption of coffee. Moreover, penetration of various pharmaceutical companies such as Novartis and Allergan is expected to fuel demand for robusta and arabica beans over the forecast period. Asia Pacific is expected to witness substantial growth over the forecast period. Increasing number of franchise outlets, coupled with rise in demand from the pharmaceutical and cosmetic industries, is driving the market in the region.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/coffee-beans-market

Further key findings from the study suggest:

By product, arabica dominated the global market with an overall revenue share of 61.2% in 2018. Robusta is anticipated to ascend at a CAGR of 7.4% over the forecast period
The food and beverages application segment held the largest share of more than 70.0% in 2018 owing to increasing number of coffee retail outlets in developing countries such as India and China
North America dominated the global market in 2018, accounting for 29.2% share of the overall revenue. This trend is projected to continue over the next few years
Middle East and Africa is anticipated to be the fastest growing market with a CAGR of 9.9% during the forecast period
Key players include Death Wish Coffee; Kicking Horse Whole Beans; Caribou Coffee; La Colombe Corsica Blend; Illycaff S.p.A.; Luigi Lavazza S.P.A.; Coffee Beans International, Inc.; La Colombe Torrefaction, INC.; and Hawaiian Isles Kona Coffee Company, Ltd.

Europe Fluorosilicic Acid Market Size Worth $74.27 Million By 2027

The Europe fluorosilicic acid market size is projected to reach USD 74.27 million by 2027, expanding at a revenue-based CAGR of 4.5%, according to a new report by Grand View Research, Inc. Rising metal surface treatment and cleaning activities across Europe are projected to drive the demand for fluorosilicic acid. Demand for metal cleaners is driven by the increasing utilization of metal components from a broad range of sectors, such as agriculture, automotive, building and construction, textile production, and electronics producers.

In recent years, 35% grade of fluorosilicic acid has gained popularity over other grades as it is used as a source of fluoride in the manufacturing of various hexafluorosilicate salts, as an organic reagent in the silylation process, as an electrolyte in Betts electrolytic process of lead refining, in wood preservation, manufacturing of disinfectants, and in the surface modification of calcium carbonate. Leading manufacturer, Honeywell International Inc., produces and supplies its fluorosilicic acid in this grade, especially to the metal surface treatment industry, while Xinxiang Yellow River Fine Chemical Industry Co., Ltd. caters to the demand from various applications including the manufacturing of fluorosilicates, disinfectants, and refining lead by electrolysis.

Manufacturing of high-density aluminum fluoride (AlF₃) is one of the major applications of fluorosilicic acid. AlF₃ is highly consumed as a molten electrolyte in the manufacturing of aluminum. Other applications of the product include the manufacturing of fluoroaluminate glass and ceramic.

Aluminum has a high demand in the manufacturing of lightweight vehicle parts in the automotive industry. The food and beverage industry highly prefers aluminum to produce cans owing to its rapid recycling rate. The metal also has a high demand in construction and aerospace industries owing to high resistance to corrosion and lightweight properties. These factors are anticipated to create a high demand for aluminum in the coming years, in turn, generating high demand for aluminum fluoride in aluminum manufacturing.

Spain was the largest consumer of fluorosilicic acid in Europe in 2019. Every year, Spain imports fluorosilicic acid, fluorosilicates, and other fluoride compounds worth over USD 15 million to cater to the domestic demand of the products in various end-use industries. China, Mexico, and Russia are the major sources of import for the country. Growing product demand in the surface treatment, electroplating, and lead refining industries are expected to propel the product consumption in the near future.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/europe-fluorosilicic-acid-market

Further key findings from the report suggest:

The demand for 35% fluorosilicic acid is expected to expand at a CAGR of 4.0% from 2020 to 2027 by volume owing to increasing demand in various hexafluorosilicate salts, as an organic reagent in the silylation process, as an electrolyte in Betts electrolytic process of lead refining
Water fluoridation accounted for a market share of 1.12% in 2019 owing to growing concerns surrounding fluorine content in drinking water
Electroplating application is expected to expand at a CAGR of 3.8% from 2020 to 2027 by revenue owing to its application in manufacturing of pure lead which is used in the manufacture of electric batteries, ammunition, and lead alloys
Russia was valued at USD 4,146.8 thousand in 2019 owing to rising application in the synthesis of hydrogen and aluminum fluoride